Many key biodiversity areas identified in Manitoba

Jan 17, 2023

The Wildlife Conservation Society of Canada has identified 75 sites across the province as potential candidates for designation as Key Biodiversity Areas (KBAs).

The designation is a relatively new conservation standard adopted in Canada in 2021. KBAs are evaluated using international criteria that recognize special areas that support rare and threatened species and ecosystems, and areas of importance within the life cycles of certain species, such as migratory stopover sites and spawning sites. The wildlife conservation society is the lead organization in the KBA Canada Secretariat, a group that also includes Birds Canada and NatureServe Canada.

The KBA designation is based on a rigorous, numerically driven approval process that considers a huge amount of data about ecosystems.

Zack Moore, Manitoba KBA Regional Coordinator for the society, is tasked with wading through the data on these 75 Manitoba sites to identify whether they meet the criteria for KBA designation.

Click here to see more...

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.